Loading
Pneumonia and Respiratory Infections · Journal article
International Journal of Community Medicine and Public Health · July 31, 2026
A consensus or society position rather than new primary data.
This is a narrative review of nafithromycin, a next-generation lactone-ketolide macrolide antibiotic developed in India. The source summarizes pharmacological and microbiological properties, including favorable pharmacokinetics, enhanced hepatic safety compared to earlier ketolides, improved ribosomal binding, and lung tissue penetration, but does not report original clinical trial data or efficacy outcomes.
Narrative review. Patients with respiratory infections caused by antimicrobial-resistant pathogens (inferred from context; not explicitly studied in this review).
Nafithromycin is India's first indigenously developed drug in the macrolide class, representing a major therapeutic breakthrough after more than three decades Nafithromycin demonstrates favorable pharmacokinetic and pharmacodynamic properties with enhanced hepatic safety compared to earlier ketolides The agent exhibits improved ribosomal binding and excellent lung tissue penetration
Specific antimicrobial spectrum and safety profile data not detailed in this abstract Nafithromycin demonstrates favorable pharmacokinetic and pharmacodynamic properties with enhanced hepatic safety compared to earlier ketolides
This review provides an overview of nafithromycin's properties but does not present clinical efficacy data or outcomes. Clinicians seeking evidence of therapeutic benefit or safety in specific populations should consult primary trial reports and comparative efficacy studies.
This is a narrative review article summarizing pharmacological and microbiological properties of nafithromycin without reporting original trial data, efficacy outcomes, or comparative clinical evidence.
As stated by the source record.
This review provides an overview of nafithromycin's properties but does not present clinical efficacy data or outcomes. Clinicians seeking evidence of therapeutic benefit or safety in specific populations should consult primary trial reports and comparative efficacy studies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
There has been a rapid increase in antimicrobial resistance, particularly among respiratory pathogens, which poses a serious global challenge to the effective treatment of infectious diseases. Nafithromycin is a next-generation macrolide antibiotic and India’s first indigenously developed drug in this class, representing a major therapeutic breakthrough after more than three decades. Based on its chemical structure, nafithromycin is categorized as a lactone-ketolide. This agent demonstrates favorable pharmacokinetic and pharmacodynamic properties along with enhanced hepatic safety when compared to earlier ketolides. Nafithromycin also exhibits improved ribosomal binding and excellent lung tissue penetration. This review focuses on the pharmacological and microbiological aspects of nafithromycin, including its antimicrobial spectrum, safety profile, clinical trial data, and overall tolerability.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.